SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer
9 references·1 citing·40 second hop
Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer (2009)Cost‐effectiveness analysis of lapatinib …Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007)Cost‐effectiveness analysis o…Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation (2006)Using and interpreting cost-e…HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)HER-2 Testing and Trastuzumab…Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Does NICE have a cost‐effecti…What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)What Is the Price of Life and…Systematic Overview of Cost-Utility Assessments in Oncology (2000)Systematic Overview of Cost-U…Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients (1998)Cost-utility model comparing …Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness in Health …A convenient approximation of life expectancy (the “DEALE”) (1982)A convenient approximation of…Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer (2016)Cost-effectiveness analysis o…Costs, effects and C/E‐ratios alongside a clinical trial (1994)Net Health Benefits (1998)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope (2006)Economic evaluation of a task-shifting intervention for common mental disorders in India (2012)Health economic evaluation: Important principles and methodology (2013)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)Decision Analysis: A Progress Report (1987)Decisions with Multiple Objectives (1993)Decisions with Multiple Objectives: Preferences and Value Tradeoffs. (1994)Determining Transition Probabilities (1994)Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities (1997)EuroQol - a new facility for the measurement of health-related quality of life (1990)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Health Care Economic Analyses and Value-Based Medicine (2003)Health Utilities Using the EQ-5D in Studies of Cancer (2007)Protected Values and Omission Bias (1999)Willingness to Pay for a Quality-adjusted Life Year (2000)Interpreting the Results of Cost-Effectiveness Studies (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)Panel on cost-effectiveness in health and medicine. (1996)Recommendations for Reporting Cost-effectiveness Analyses (1996)Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine (1996)Cost effectiveness of gene expression profiling for early stage breast cancer (2012)The economic pressures for biosimilar drug use in cancer medicine (2012)Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer (2019)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2007)The Markov Process in Medical Prognosis (1983)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)EQ-SD: a measure of health status from the EuroQol Group (2001)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)
this work references cited by second hop

References

  • 1996Cost-Effectiveness in Health and Medicine7,192 cited
  • 2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited
  • 2003What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?588 cited
  • 1982A convenient approximation of life expectancy (the “DEALE”)480 cited
  • 2000Systematic Overview of Cost-Utility Assessments in Oncology296 cited
  • 2006Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation279 cited
  • 2004HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis230 cited
  • 2007Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer120 cited
  • 1998Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients64 cited

Cited by

  • 2016Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer56 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work